Conv. Plasma
Nigella Sativa

All paxlovid studies
Meta analysis
study COVID-19 treatment researchPaxlovidPaxlovid (more..)
Melatonin Meta
Metformin Meta
Antihistamines Meta
Azvudine Meta Molnupiravir Meta
Bromhexine Meta
Budesonide Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta PPIs Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

All Studies   All Outcomes    Recent:   

Efficacy and safety of Huashi Baidu granule plus Nirmatrelvir-Ritonavir combination therapy in patients with high-risk factors infected with Omicron (B.1.1.529): A multi-arm single-center, open-label, randomized controlled trial

Aug 2023  
  Source   PDF   All Studies   Meta AnalysisMeta
Severe case -2% Improvement Relative Risk Discharge -6% Viral clearance 12% Paxlovid  Yu et al.  LATE TREATMENT  RCT Is late treatment with paxlovid beneficial for COVID-19? RCT 208 patients in China (April - June 2022) Trial compares with Huashi Baidu, results vs. placebo may differ Improved viral clearance with paxlovid (not stat. sig., p=0.33) Yu et al., Phytomedicine, August 2023 Favorspaxlovid FavorsHuashi Baidu 0 0.5 1 1.5 2+
RCT 312 hospitalized COVID-19 patients in China, showing no significant difference between paxlovid and Huashi Baidu treatment. Combination therapy showed improved results to either treatment alone.
risk of severe case, 1.9% higher, RR 1.02, p = 1.00, treatment 3 of 103 (2.9%), control 3 of 105 (2.9%).
risk of no hospital discharge, 6.3% higher, RR 1.06, p = 0.78, treatment 49 of 103 (47.6%), control 47 of 105 (44.8%).
risk of no viral clearance, 12.0% lower, HR 0.88, p = 0.33, treatment 30 of 103 (29.1%), control 34 of 105 (32.4%), NNT 31.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Yu et al., 16 Aug 2023, Randomized Controlled Trial, China, peer-reviewed, 18 authors, study period 18 April, 2022 - 5 June, 2022, this trial compares with another treatment - results may be better when compared to placebo, trial ChiCTR2200059390.
This PaperPaxlovidAll
{ 'indexed': {'date-parts': [[2023, 8, 27]], 'date-time': '2023-08-27T14:11:10Z', 'timestamp': 1693145470222}, 'reference-count': 27, 'publisher': 'Elsevier BV', 'license': [ { 'start': { 'date-parts': [[2023, 11, 1]], 'date-time': '2023-11-01T00:00:00Z', 'timestamp': 1698796800000}, 'content-version': 'tdm', 'delay-in-days': 0, 'URL': ''}, { 'start': { 'date-parts': [[2023, 11, 1]], 'date-time': '2023-11-01T00:00:00Z', 'timestamp': 1698796800000}, 'content-version': 'stm-asf', 'delay-in-days': 0, 'URL': ''}, { 'start': { 'date-parts': [[2023, 11, 1]], 'date-time': '2023-11-01T00:00:00Z', 'timestamp': 1698796800000}, 'content-version': 'stm-asf', 'delay-in-days': 0, 'URL': ''}, { 'start': { 'date-parts': [[2023, 11, 1]], 'date-time': '2023-11-01T00:00:00Z', 'timestamp': 1698796800000}, 'content-version': 'stm-asf', 'delay-in-days': 0, 'URL': ''}, { 'start': { 'date-parts': [[2023, 11, 1]], 'date-time': '2023-11-01T00:00:00Z', 'timestamp': 1698796800000}, 'content-version': 'stm-asf', 'delay-in-days': 0, 'URL': ''}, { 'start': { 'date-parts': [[2023, 11, 1]], 'date-time': '2023-11-01T00:00:00Z', 'timestamp': 1698796800000}, 'content-version': 'stm-asf', 'delay-in-days': 0, 'URL': ''}], 'content-domain': {'domain': ['', ''], 'crossmark-restriction': True}, 'published-print': {'date-parts': [[2023, 11]]}, 'DOI': '10.1016/j.phymed.2023.155025', 'type': 'journal-article', 'created': {'date-parts': [[2023, 8, 16]], 'date-time': '2023-08-16T15:39:30Z', 'timestamp': 1692200370000}, 'page': '155025', 'update-policy': '', 'source': 'Crossref', 'is-referenced-by-count': 0, 'title': 'Efficacy and safety of Huashi Baidu granule plus Nirmatrelvir-Ritonavir combination therapy in ' 'patients with high-risk factors infected with Omicron (B.1.1.529): A multi-arm single-center, ' 'open-label, randomized controlled trial', 'prefix': '10.1016', 'volume': '120', 'author': [ { 'ORCID': '', 'authenticated-orcid': False, 'given': 'Zhuo', 'family': 'Yu', 'sequence': 'first', 'affiliation': []}, {'given': 'Yanxi', 'family': 'Zheng', 'sequence': 'additional', 'affiliation': []}, {'given': 'Bowu', 'family': 'Chen', 'sequence': 'additional', 'affiliation': []}, {'given': 'Jia', 'family': 'Lv', 'sequence': 'additional', 'affiliation': []}, {'given': 'Xiaojun', 'family': 'Zhu', 'sequence': 'additional', 'affiliation': []}, {'given': 'Binyi', 'family': 'Shang', 'sequence': 'additional', 'affiliation': []}, {'given': 'Yuping', 'family': 'Xv', 'sequence': 'additional', 'affiliation': []}, {'given': 'Ru', 'family': 'Tao', 'sequence': 'additional', 'affiliation': []}, {'given': 'Yanbing', 'family': 'Yang', 'sequence': 'additional', 'affiliation': []}, {'given': 'Jun', 'family': 'Cong', 'sequence': 'additional', 'affiliation': []}, {'given': 'Dan', 'family': 'Li', 'sequence': 'additional', 'affiliation': []}, {'given': 'Huan', 'family': 'Wu', 'sequence': 'additional', 'affiliation': []}, {'given': 'Wenchao', 'family': 'Qv', 'sequence': 'additional', 'affiliation': []}, {'given': 'Xiyi', 'family': 'Zhang', 'sequence': 'additional', 'affiliation': []}, {'given': 'Chengbin', 'family': 'Xv', 'sequence': 'additional', 'affiliation': []}, { 'ORCID': '', 'authenticated-orcid': False, 'given': 'Hai', 'family': 'Feng', 'sequence': 'additional', 'affiliation': []}, {'given': 'Weian', 'family': 'Yuan', 'sequence': 'additional', 'affiliation': []}, { 'ORCID': '', 'authenticated-orcid': False, 'given': 'Yueqiu', 'family': 'Gao', 'sequence': 'additional', 'affiliation': []}], 'member': '78', 'reference': [ { 'key': '10.1016/j.phymed.2023.155025_bib0001', 'doi-asserted-by': 'crossref', 'DOI': '10.3389/fmed.2022.849217', 'article-title': 'The biological functions and clinical significance of SARS-CoV-2 ' 'variants of corcern', 'volume': '9', 'author': 'Akkiz', 'year': '2022', 'journal-title': 'Front. Med.'}, { 'key': '10.1016/j.phymed.2023.155025_bib0002', 'series-title': 'StatPearls', 'article-title': 'Emerging variants of SARS-CoV-2 and novel therapeutics against ' 'coronavirus (COVID-19), updated 2022 May 12 ed', 'author': 'Aleem', 'year': '2022'}, { 'key': '10.1016/j.phymed.2023.155025_bib0003', 'doi-asserted-by': 'crossref', 'first-page': '1763', 'DOI': '10.1126/science.1085658', 'article-title': 'Coronavirus main proteinase (3CLpro) structure: basis for design of ' 'anti-SARS drugs', 'volume': '300', 'author': 'Anand', 'year': '2003', 'journal-title': 'Science'}, { 'key': '10.1016/j.phymed.2023.155025_bib0004', 'doi-asserted-by': 'crossref', 'first-page': '3864', 'DOI': '10.21037/apm-20-1759', 'article-title': 'The pharmacological mechanism of Huashi Baidu Formula for the treatment ' 'of COVID-19 by combined network pharmacology and molecular docking', 'volume': '10', 'author': 'Cai', 'year': '2021', 'journal-title': 'Ann. Palliat Med.'}, { 'key': '10.1016/j.phymed.2023.155025_bib0005', 'doi-asserted-by': 'crossref', 'first-page': '452', 'DOI': '10.1136/bmj.310.6977.452', 'article-title': 'The number needed to treat: a clinically useful measure of treatment ' 'effect', 'volume': '310', 'author': 'Cook', 'year': '1995', 'journal-title': 'BMJ'}, { 'key': '10.1016/j.phymed.2023.155025_bib0006', 'doi-asserted-by': 'crossref', 'DOI': '10.1016/j.drup.2021.100794', 'article-title': 'An update on drugs with therapeutic potential for SARS-CoV-2 (COVID-19) ' 'treatment', 'volume': '59', 'author': 'Drozdzal', 'year': '2021', 'journal-title': 'Drug Resist. Updat.'}, { 'key': '10.1016/j.phymed.2023.155025_bib0007', 'doi-asserted-by': 'crossref', 'first-page': 'o1037', 'DOI': '10.1136/bmj.o1037', 'article-title': 'COVID-19: what is the evidence for the antiviral Paxlovid?', 'volume': '377', 'author': 'Extance', 'year': '2022', 'journal-title': 'BMJ'}, { 'key': '10.1016/j.phymed.2023.155025_bib0008', 'doi-asserted-by': 'crossref', 'first-page': '88', 'DOI': '10.1016/j.bbrc.2020.10.102', 'article-title': 'Evolution patterns of SARS-CoV-2: snapshot on its genome variants', 'volume': '538', 'author': 'Giovanetti', 'year': '2021', 'journal-title': 'Biochem. Biophys. Res. Commun.'}, { 'key': '10.1016/j.phymed.2023.155025_bib0009', 'doi-asserted-by': 'crossref', 'first-page': '693', 'DOI': '10.1056/NEJMoa2021436', 'article-title': 'Dexamethasone in hospitalized patients with COVID-19', 'volume': '384', 'author': 'Horby', 'year': '2021', 'journal-title': 'N. Engl. J. Med.'}, { 'key': '10.1016/j.phymed.2023.155025_bib0010', 'doi-asserted-by': 'crossref', 'first-page': '1330', 'DOI': '10.1001/jama.2020.17023', 'article-title': 'Association between administration of systemic corticosteroids and ' 'mortality among critically ill patients with COVID-19: a meta-analysis', 'volume': '324', 'author': 'Sterne', 'year': '2020', 'journal-title': 'JAMA'}, { 'key': '10.1016/j.phymed.2023.155025_bib0011', 'doi-asserted-by': 'crossref', 'first-page': '1397', 'DOI': '10.1056/NEJMoa2118542', 'article-title': 'Oral Nirmatrelvir for high-risk, nonhospitalized adults with COVID-19', 'volume': '386', 'author': 'Hammond', 'year': '2022', 'journal-title': 'N. Engl. J. Med.'}, { 'key': '10.1016/j.phymed.2023.155025_bib0012', 'doi-asserted-by': 'crossref', 'first-page': '4085', 'DOI': '10.1111/febs.12936', 'article-title': 'From SARS to MERS: crystallographic studies on coronaviral proteases ' 'enable antiviral drug design', 'volume': '281', 'author': 'Hilgenfeld', 'year': '2014', 'journal-title': 'FEBS J.'}, { 'key': '10.1016/j.phymed.2023.155025_bib0013', 'doi-asserted-by': 'crossref', 'first-page': '1610', 'DOI': '10.1001/jama.2019.3087', 'article-title': 'Reporting of multi-arm parallel-group randomized trials: extension of ' 'the CONSORT 2010 statement', 'volume': '321', 'author': 'Juszczak', 'year': '2019', 'journal-title': 'JAMA'}, { 'key': '10.1016/j.phymed.2023.155025_bib0014', 'doi-asserted-by': 'crossref', 'first-page': '681', 'DOI': '10.1007/s11684-020-0801-x', 'article-title': 'The role played by traditional Chinese medicine in preventing and ' 'treating COVID-19 in China', 'volume': '14', 'author': 'Li', 'year': '2020', 'journal-title': 'Front. Med.'}, { 'key': '10.1016/j.phymed.2023.155025_bib0015', 'doi-asserted-by': 'crossref', 'DOI': '10.1016/j.phymed.2021.153671', 'article-title': 'Combination of Hua Shi Bai Du granule (Q-14) and standard care in the ' 'treatment of patients with coronavirus disease 2019 (COVID-19): a ' 'single-center, open-label, randomized controlled trial', 'volume': '91', 'author': 'Liu', 'year': '2021', 'journal-title': 'Phytomedicine'}, { 'key': '10.1016/j.phymed.2023.155025_bib0016', 'doi-asserted-by': 'crossref', 'first-page': '94', 'DOI': '10.1186/s13020-020-00375-1', 'article-title': 'Reflections on treatment of COVID-19 with traditional Chinese medicine', 'volume': '15', 'author': 'Luo', 'year': '2020', 'journal-title': 'Chin. Med.'}, { 'key': '10.1016/j.phymed.2023.155025_bib0017', 'doi-asserted-by': 'crossref', 'first-page': 'n2713', 'DOI': '10.1136/bmj.n2713', 'article-title': "COVID-19: Pfizer's paxlovid is 89% effective in patients at risk of " 'serious illness, company reports', 'volume': '375', 'author': 'Mahase', 'year': '2021', 'journal-title': 'BMJ'}, { 'key': '10.1016/j.phymed.2023.155025_bib0018', 'doi-asserted-by': 'crossref', 'first-page': '1586', 'DOI': '10.1126/science.abl4784', 'article-title': 'An oral SARS-CoV-2 M(pro) inhibitor clinical candidate for the ' 'treatment of COVID-19', 'volume': '374', 'author': 'Owen', 'year': '2021', 'journal-title': 'Science'}, { 'key': '10.1016/j.phymed.2023.155025_bib0019', 'doi-asserted-by': 'crossref', 'DOI': '10.1016/j.virusres.2020.198057', 'article-title': 'Potential drugs for the treatment of the novel coronavirus pneumonia ' '(COVID-19) in China', 'volume': '286', 'author': 'Pan', 'year': '2020', 'journal-title': 'Virus Res.'}, { 'key': '10.1016/j.phymed.2023.155025_bib0020', 'article-title': 'Traditional Chinese medicine for COVID-19 treatment', 'volume': '155', 'author': 'Ren', 'year': '2020', 'journal-title': 'Pharmacol. Res.'}, { 'key': '10.1016/j.phymed.2023.155025_bib0021', 'doi-asserted-by': 'crossref', 'DOI': '10.1016/j.phymed.2020.153367', 'article-title': 'Efficacy and safety of Chinese herbal medicine versus ' 'Lopinavir-Ritonavir in adult patients with coronavirus disease 2019: a ' 'non-randomized controlled trial', 'volume': '81', 'author': 'Shi', 'year': '2021', 'journal-title': 'Phytomedicine'}, { 'key': '10.1016/j.phymed.2023.155025_bib0022', 'doi-asserted-by': 'crossref', 'unstructured': 'Su, H., Yao, S., Zhao, W., Li, M., Liu, J., Shang, W., Xie, H., Ke, C., ' 'Gao, M., Yu, K., Liu, H., Shen, J., Tang, W., Zhang, L., Zuo, J., Jiang, ' 'H., Bai, F., Wu, Y., Ye, Y., Xu, Y., 2020. Discovery of baicalin and ' 'baicalein as novel, natural product inhibitors of SARS-CoV-2 3CL ' 'protease in vitro. Biorxiv.', 'DOI': '10.1101/2020.04.13.038687'}, { 'key': '10.1016/j.phymed.2023.155025_bib0023', 'doi-asserted-by': 'crossref', 'first-page': '1345', 'DOI': '10.1080/03639045.2020.1788070', 'article-title': 'Network pharmacology and molecular docking analysis on molecular ' 'targets and mechanisms of Huashi Baidu formula in the treatment of ' 'COVID-19', 'volume': '46', 'author': 'Tao', 'year': '2020', 'journal-title': 'Drug Dev. Ind. Pharm.'}, { 'key': '10.1016/j.phymed.2023.155025_bib0024', 'doi-asserted-by': 'crossref', 'DOI': '10.1016/j.antiviral.2022.105252', 'article-title': 'Remdesivir, Molnupiravir and Nirmatrelvir remain active against ' 'SARS-CoV-2 Omicron and other variants of concern', 'volume': '198', 'author': 'Vangeel', 'year': '2022', 'journal-title': 'Antiviral Res.'}, { 'key': '10.1016/j.phymed.2023.155025_bib0025', 'first-page': '28', 'article-title': 'Study of molecular mechanism of Huashibaidu decoction on COVID-19 based ' 'on network pharmacology and molecular docking technology', 'volume': '36', 'author': 'Xie', 'year': '2020', 'journal-title': 'Pharmcol. Clin. Chin. Mater. Med.'}, { 'key': '10.1016/j.phymed.2023.155025_bib0026', 'doi-asserted-by': 'crossref', 'first-page': '420', 'DOI': '10.1016/S2213-2600(20)30076-X', 'article-title': 'Pathological findings of COVID-19 associated with acute respiratory ' 'distress syndrome', 'volume': '8', 'author': 'Xu', 'year': '2020', 'journal-title': 'Lancet Respir. Med.'}, { 'key': '10.1016/j.phymed.2023.155025_bib0027', 'first-page': '672', 'article-title': 'Material basis research of anti-COVID-19 Huashibaidu granule gormula', 'volume': '22', 'author': 'Yang', 'year': '2020', 'journal-title': 'Mod. Chin. Med.'}], 'container-title': 'Phytomedicine', 'original-title': [], 'language': 'en', 'link': [ { 'URL': '', 'content-type': 'text/xml', 'content-version': 'vor', 'intended-application': 'text-mining'}, { 'URL': '', 'content-type': 'text/plain', 'content-version': 'vor', 'intended-application': 'text-mining'}], 'deposited': { 'date-parts': [[2023, 8, 26]], 'date-time': '2023-08-26T10:21:02Z', 'timestamp': 1693045262000}, 'score': 1, 'resource': {'primary': {'URL': ''}}, 'subtitle': [], 'short-title': [], 'issued': {'date-parts': [[2023, 11]]}, 'references-count': 27, 'alternative-id': ['S0944711323003860'], 'URL': '', 'relation': {}, 'ISSN': ['0944-7113'], 'subject': [ 'Complementary and alternative medicine', 'Drug Discovery', 'Pharmaceutical Science', 'Pharmacology', 'Molecular Medicine'], 'container-title-short': 'Phytomedicine', 'published': {'date-parts': [[2023, 11]]}, 'assertion': [ {'value': 'Elsevier', 'name': 'publisher', 'label': 'This article is maintained by'}, { 'value': 'Efficacy and safety of Huashi Baidu granule plus Nirmatrelvir-Ritonavir ' 'combination therapy in patients with high-risk factors infected with Omicron ' '(B.1.1.529): A multi-arm single-center, open-label, randomized controlled trial', 'name': 'articletitle', 'label': 'Article Title'}, {'value': 'Phytomedicine', 'name': 'journaltitle', 'label': 'Journal Title'}, { 'value': '', 'name': 'articlelink', 'label': 'CrossRef DOI link to publisher maintained version'}, {'value': 'article', 'name': 'content_type', 'label': 'Content Type'}, {'value': '© 2023 Published by Elsevier GmbH.', 'name': 'copyright', 'label': 'Copyright'}], 'article-number': '155025'}
Late treatment
is less effective
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop